Jan, 2013

U.S.A.
News / Therapeutic Area News
FDA Accepts Supplemental New Drug Application For Tarceva® (erlotinib) Tablets For Genetically Distinct Form Of Advanced Lung Cancer
Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the U.S. Food and...
Read More

Dec, 2012

U.S.A.
News / Therapeutic Area News
Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and...
Read More

Nov, 2012

U.S.A.
News / Therapeutic Area News
Astellas Submits Supplemental New Drug Application to FDA for Tarceva® as a First-Line Therapy in Genetically Distinct Form of Non-Small Cell Lung Cancer
Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a...
Read More

Oct, 2012

U.S.A.
News / Therapeutic Area News
MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies
Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that MYRBETRIQ™...
Read More

Sep, 2012

U.S.A.
News / Therapeutic Area News
Astellas Submits U.S. New Drug Application for Tacrolimus Extended Release Capsules, a Prophylaxis of Organ Rejection in Transplant Recipients
Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a New...
Read More